MeiraGTx Holdings Plc

MeiraGTx Holdings Plc has seen significant stock performance, with notable increases over various time frames, including a year-to-date rise of nearly 70%. However, the company faces challenges such as a negative book value and declining profits, raising concerns about the sustainability of its recent gains.

MeiraGTx Holdings Plc has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant stock price growth over the past year, with an impressive return on equity, despite lacking a dividend yield and facing a negative price-to-book ratio.

MeiraGTx Holdings Plc has achieved a new 52-week high, reflecting a significant year-over-year performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 613 million, the company demonstrates effective management through a high return on equity, despite being loss-making and lacking a dividend yield.

MeiraGTx Holdings Plc has achieved a new 52-week high, reflecting a significant increase from its previous low. The company, with a market capitalization of USD 613 million, operates in the Pharmaceuticals & Biotechnology sector and has notable performance metrics, including a high return on equity and a unique financial structure.

MeiraGTx Holdings Plc, a small-cap in the Pharmaceuticals & Biotechnology sector, saw its stock rise significantly today, reaching an intraday high. Over the past month, the stock has performed well, but the company faces challenges, including a negative book value and declining operating profit, raising concerns about its long-term financial health.

MeiraGTx Holdings Plc, a small-cap biotechnology firm, has seen significant stock gains recently, outperforming the S&P 500. While the company has shown strong short-term performance and impressive annual returns, it faces challenges such as a negative book value and declining operating profit, raising concerns about its long-term fundamentals.

MeiraGTx Holdings Plc, a small-cap biotechnology firm, saw its stock decline significantly today, reaching an intraday low. Despite this, the company has experienced substantial growth over the past year. However, concerns about its long-term fundamentals persist, particularly regarding its debt servicing capabilities.

MeiraGTx Holdings Plc has reported a notable increase in net sales for the quarter ending June 2025, alongside a decline in raw material costs, enhancing financial health. However, the company faces challenges with a significant net loss, low return on capital employed, and high debt-equity ratio, indicating potential financial strain.

MeiraGTx Holdings Plc achieved a new 52-week high of USD 9.73 on November 10, 2025, reflecting a significant increase from its previous low. The company, with a market cap of USD 601 million, operates in the Pharmaceuticals & Biotechnology sector and is currently loss-making.

MeiraGTx Holdings Plc has achieved a new 52-week high of USD 9.44, reflecting an impressive one-year performance of 82.08%. The company, with a market capitalization of USD 601 million, continues to face challenges, including a significant debt-to-equity ratio and ongoing losses.

MeiraGTx Holdings Plc, a microcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price slightly decrease to 7.83. Over the past year, it achieved an impressive return of 84.24%, significantly surpassing the S&P 500. The company's recent performance reflects its resilience in a competitive market.

MeiraGTx Holdings Plc, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced recent stock price fluctuations, trading between 8.20 and 8.51. The company has shown significant annual returns, outperforming the S&P 500, though its longer-term performance over three and five years has declined.

MeiraGTx Holdings Plc, a microcap in the Pharmaceuticals and Biotechnology sector, has experienced significant stock fluctuations, with a recent trading range indicating active market engagement. While the company has outperformed the S&P 500 over the past year and year-to-date, longer-term performance reveals challenges and volatility.